Disturbed endothelial cell signaling in tumor progression and therapy resistance

Curr Opin Cell Biol. 2023 Nov 28;86:102287. doi: 10.1016/j.ceb.2023.102287. Online ahead of print.ABSTRACTGrowth of new blood vessels is considered requisite to cancer progression. Recent findings revealed that in addition to inducing angiogenesis, tumor-derived factors alter endothelial cell gene transcription within the tumor mass but also systemically throughout the body. This subsequently contributes to immunosuppression, altered metabolism, therapy resistance and metastasis. Clinical studies demonstrated that targeting the endothelium can increase the success rate of immunotherapy. Single-cell technologies revealed remarkable organ-specific endothelial heterogeneity that becomes altered by the presence of a tumor. In metastases, endothelial transcription differs remarkably between newly formed and co-opted vessels which may provide a basis for developing new therapies to target endothelial cells and overcome therapy resistance more effectively. This review addresses how cancers impact the endothelium to facilitate tumor progression.PMID:38029706 | DOI:10.1016/j.ceb.2023.102287
Source: Current Opinion in Cell Biology - Category: Cytology Authors: Source Type: research